Type 2 immunopathology is a cardinal feature of allergic diseases and involves cooperation between adaptive immunity and innate effector responses. Virtually all cell types relevant to this pathology generate leukotriene and/or prostaglandin mediators that derive from arachidonic acid, express receptors for such mediators, or both. Recent studies highlight prominent functions for these mediators in communication between the innate and adaptive immune systems, as well as amplification or suppression of type 2 effector responses. This review focuses on recent advances and insights, and highlights existing and potential therapeutic applications of drugs that target these mediators or their receptors, with a special emphasis on their regulation of the innate and adaptive lymphocytes relevant to type 2 immunopathology. (J Allergy Clin Immunol 2018;141:1182-90.) 
Asthma, eosinophilic esophagitis (EoE), and chronic rhinosinusitis have become markedly more common in Western societies in the past half century. These diseases all involve end-organ dysfunction caused by persistent activation of the immune system, resulting in eosinophil-rich (type 2) immunopathology. Because these diseases cause substantial morbidity, developing new therapeutics and preventive strategies is a high priority. Such development requires an in-depth understanding of the underlying molecular and cellular mechanisms.
Allergic diseases involve prominent contributions from both the innate and adaptive immune systems. Thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 are generated primarily by barrier epithelial cells (EpCs) and released in the innate response to pathogens, antigens, and local injury (Fig 1) . Their expression can also be persistently upregulated with severe disease, resulting in sustained pathology. Of their target cells, group 2 innate lymphoid cells (ILC2s) generate especially large quantities of type 2 cytokines (IL-5, IL-13, and IL-9)
1-3 when stimulated with barrier-derived cytokines, 4 as do mast cells, basophils, and certain populations of T H 2 cells. In mouse models of helminth infection, ILC2s are sufficient to induce mucosal eosinophilia and goblet cell hyperplasia, even in mice lacking adaptive immune systems. 5 Although less is known about the role of ILC2s in human disease, recent studies implicate ILC2s as potentially important sources of type 2 cytokines in patients with asthma, chronic rhinosinusitis, and EoE. Additionally, a population of conventional human T H 2 cells identified exclusively in subjects with allergic disease display ILC2-like features (including the expression and function of receptors for TSLP, IL-33, and IL-25). These cells, termed pathogenic effector T H 2 cells or ''T H 2A'' cells have innate-like functions such that they no longer require specific antigen exposure for activation and type 2 cytokine production. 9, 10 They might account for the majority of cytokine-producing T cells in patients with allergic disease. Thus the mechanisms that control innate and adaptive lymphoid effectors, both positively and negatively, carry not only pathobiological significance but also potential therapeutic implications, especially in patients with severe disease.
Lipid mediators derived from arachidonic acid (AA) play substantial roles in the control of ILC2 and T H 2 cell function. AA is stored in membrane phospholipids and released at high levels on cell activation. AA is metabolized to prostaglandins (PGs), leukotrienes (LTs), and other bioactive mediators through specific synthetic enzyme pathways.
2,11 AA-derived bioactive lipids have receptor-specific inductive and suppressive effects that can influence the duration and magnitude of the immunopathology and end-organ dysfunction. This carries the potential for lipid mediator-targeted therapies to substantially affect allergic diseases. [12] [13] [14] [15] This review will cover our current understanding of the proinflammatory and anti-inflammatory functions of AA-derived lipids, their cells of origin, and their receptors. Although many cell types (including mast cells, basophils, and eosinophils) relevant to type 2 immunopathology express these receptors, we will focus primarily on the effects of lipid mediators on ILC2s and T H 2 cells, as well as their upstream cytokine sources, where applicable, because of the recent increase in published literature on this subject. Production and effects of lipid mediators on type 2 inflammation. EpCs release IL-33, IL-25, and TSLP, which activate ILC2s and T H 2 cells and lead to T H 2 cytokine release. CysLTs, generated by mast cells, eosinophils, macrophages, and platelets, act on ILC2s and T H 2 cells. Mast cells and platelets are prime producers of PGD 2 , which supports the type 2 response by activating ILC2s and T H 2 cells and suppresses the T H 1 response by inhibiting T-cell production of IFN-g and IL-2. PGE 2 , a product from EpCs, macrophages, and fibroblasts, suppresses activation of ILC2s but also enhances IL-33 synthesis by macrophages and potentiates a T H 17-like effector response from group 3 innate lymphoid cells (ILC3) and T cells. PGE 2 also has anti-inflammatory effects because it can block mast cell activation. PGI 2 has mostly anti-inflammatory roles on ILC2s, T H 2 cells, eosinophils, and follicular DCs. LXA 4 can also modulate the type 2 immune response by suppressing PGD 2 -derived activation of ILC2s and promoting eosinophil apoptosis by natural killer (NK) cells.
CYSTEINYL LEUKOTRIENES Biosynthesis
LTs are 5-lipoxygenase (5-LO)-derived AA products. 5-LO, while anchored to a membrane-anchored 5-LO-activating protein, oxidizes AA to generate 5-hydroxyperoxyeicosatetraenoic acid and then to generate 5-hydroxytetraenoic acid (5-HETE). 5-LO further dehydrates 5-HETE to LTA 4 , an unstable intermediate. 16 Neutrophils hydrolyze LTA 4 to LTB 4 through a cytosolic LTA 4 hydrolase enzyme, whereas eosinophils and basophils conjugate LTA 4 to reduced glutathione by leukotriene C 4 synthase (LTC 4 S) to form LTC 4 , the parent of the cysteinyl leukotrienes (cysLTs). Mast cells and macrophages express both terminal enzymes, although both cell types tend to generate LTC 4 in excess of LTB 4 . Platelets lack 5-LO or 5-LO-activating protein and cannot generate LTA 4 but do express LTC 4 S and can convert excess granulocyte-derived LTA 4 to LTC 4 , thus increasing cysLT levels with inflammation. LTC 4 is exported to the extracellular space, where it is converted first to LTD 4 through enzymatic removal of glutamic acid from the glutathione adduct and then rapidly to the stable end-metabolite LTE 4 through glycine removal. 16 LTE 4 is excreted unchanged in urine. The stability of LTE 4 and instability of LTD 4 account for the typical rank order concentrations of LTE 4 > LTC 4 >> LTD 4 in extracellular fluids (Fig 2) .
Receptors
LTC 4 , LTD 4 , and LTE 4 have varied potencies and sites of action caused by the existence of at least 3 different receptors, termed cysteinyl leukotriene receptor type 1 (CysLT 1 R), cysteinyl leukotriene receptor type 2 (CysLT 2 R), and cysteinyl leukotriene receptor type 3 (CysLT 3 R). CysLT 1 R is a high-affinity LTD 4 receptor, [17] [18] [19] whereas CysLT 2 R binds to LTD 4 and LTC 4 with equal avidity. 20, 21 CysLT 3 R (previously known as GPR99) preferentially binds LTE 4 . 22, 23 Studies with selective antagonists verified that cysLTs acting at CysLT 1 R account for a substantial fraction of the bronchoconstriction on inhalational allergen challenge in atopic asthmatic patients and that cysLTs participate in asthma exacerbations. 24, 25 To date, the lack of clinically available antagonists has precluded a systematic examination of the roles of CysLT 2 R and GPR99/CysLT 3 R in human subjects. Studies in transgenic mice (see below) demonstrate that each cysLT receptor has a unique set of functions and cellular targets in the induction and amplification of type 2 immunopathology (Table I) .
Clinical correlation
Patients with spontaneous asthma exacerbations have high urinary LTE 4 levels relative to their baseline values. Both the 5-LO inhibitor zileuton and selective CysLT 1 R antagonists provide significant protection from asthma exacerbations in controlled trials, verifying the contribution of cysLTs to asthma exacerbations. 13, 14, 26 Baseline levels of urinary LTE 4 are significantly increased in obese asthmatic patients than in nonobese asthmatic patients. 27 In preschool children increased urinary LTE 4 levels correlate with high serum IgE levels and strongly predict subsequent asthma development. 28 The early observations that inhaled LTE 4 induced eosinophil accumulation in the bronchial mucosa of patients with mild asthma were the first evidence that cysLTs promote type 2 immunity. 29 Administration of zileuton or montelukast (CysLT 1 R inhibitor) reduce blood eosinophil counts. [30] [31] [32] In patients with aspirin-exacerbated respiratory disease (AERD), cysLT overproduction is accompanied by severe asthma and chronic eosinophilic rhinosinusitis. The symptomatic improvement afforded these patients by cysLT-targeted drugs is consistent with the role of cysLTs as inducers and amplifiers of type 2 immunopathology in human subjects, especially those with AERD (Fig 2) .
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Activation of T H cells and ILC2s
Human T H 2 cells, but not T H 1 cells, express CysLT 1 R, and their stimulation with cysLTs elicited IL-13 production. 4, 35 Curiously, although the response is completely blocked by CysLT 1 R antagonists, LTE 4 is more potent than LTD 4 for this effect. In addition, the effect of LTE 4 on human T H 2 cells is amplified by PGD 2 , which acts synergistically with LTE 4 to induce not only T H 2 cytokines but also IL-22, IL-8, and GM-CSF. 36 Human ILC2s also express CysLT 1 R, and this expression is greater in cells from atopic subjects compared with nonatopic control subjects. Isolated human ILC2s showed induced migration, survival, and type 2 cytokine production on ex vivo stimulation with LTE 4 to a greater extent than with LTD 4 . 37 4 , and LTE 4 can all expand and activate lung ILC2s in mice, the effects of LTE 4 appeared to be indirect and (unlike human ILC2s) independent of CysLT 1 R. 39, 41 These studies support a role for cysLTs in amplifying inflammation in type 2 immunity by acting at both the innate and adaptive lymphocyte compartments.
Effects on EpCs
Human nasal EpCs express both CysLT 1 R and CysLT 2 R based on immunostaining of mucosal biopsy specimens. 42 Although studies examining the role of cysLTs in EpC function are sparse, CysLT 1 R signaling conferred protection from epithelial damage in a model of airway injury induced by (Cl 2 )-elicited oxidative stress. 43 CysLT 3 R/GPR99 is expressed dominantly by murine respiratory EpCs. Intranasal administration of LTE 4 to wild-type (WT) mice elicited mucin release by goblet cells, which was abrogated in CysLT 3 R-null mice. Endogenous CysLTs-GPR99 signaling was also crucial for Alternaria alternata-induced mucin release. 23 Additionally, lung EpC-derived IL-33 is sharply increased in Dermatophagoides farinae extract (Df)-treated microsomal PGE 2 synthase (Ptges) null mice, which show strong cysLT-driven type 2 pathology relative to WT control mice. The increase in IL-33 levels was abrogated in LTC 4 S-null mice, which was attributable to endogenous cysLT signaling through CysLT 2 R. 41, 44 Given the ability of IL-33 to activate ILC2s synergistically with cysLTs acting at CysLT 1 R, 39 these findings imply cooperation between at least 2 cysLT receptors in regulating ILC2 homeostasis in inflammation.
PGs Biosynthesis
Essentially all cell types generate COX products or PGs. Two COX enzymes, COX-1 and COX-2, cyclize AA to PGG 2 and then to PGH 2 through endoperoxidase activity. COX-1 accounts for constitutive PG generation in most cell types, whereas COX-2 expression can be induced or upregulated in response to signaling through exogenous (eg, endotoxin) and endogenous (eg, IL-1 PGI 2 synthase is expressed prominently by endothelial cells and follicular dendritic cells (DCs), which generate PGI 2 (also known as prostacyclin) as their dominant COX pathway product. Finally, the human PGF synthase enzyme is expressed primarily in lungs, where it catalyzes 2 reactions: formation of PGF 2 a from PGH 2 and conversion of PGD 2 to 9a, 11b-PGF, which is a potent bronchoconstrictor. 50, 51 All of the terminal PGs have short biological half-lives, suggesting that they function primarily in autocrine circuits, as well as paracrine cell-cell interactions over short distances (Fig 2) . 47 
PGD 2
Receptors. PGD 2 signals directly through 2 G proteincoupled receptors (GPCRs) termed D prostanoid (DP) 1 and DP 2 , respectively, or chemoattractant receptor-homologous molecule expressed on T H 2 cells (CRTH2).
52 DP 1 receptors are homologous to other PG-responsive GPCRs, signal through stimulatory G proteins, and are expressed by endothelial cells, platelets, DCs, mast cells, eosinophils, basophils, and T cells.
53 DP 2 receptors are more homologous to chemokine receptors, signal through inhibitory G proteins, and are strongly expressed by eosinophils, basophils, ILC2s, and human T H 2 cells (see below). 53 Combined with the fact that mast cells are the dominant sources of PGD 2 , distribution of the DP receptors suggests its capacity to promote communication from mast cells to both the innate and adaptive immune systems. The PGD 2 metabolite 9a-11b-PGF 2 functions as a bronchoconstrictor through T prostanoid receptors and likely accounts for the decrease in airflow that results from inhalation of PGD 2 by human subjects. 51, 54 Another metabolite, 15-deoxy PGJ2a, is an agonist for peroxisome proliferatoractivated receptor g. 55, 56 Thus some PGD 2 effects in vivo likely occur independently of its cognate GPCRs (Table I) .
Clinical correlation. PGD 2 is released from airway mast cells in response to provocative challenges of susceptible hosts with allergens or (in the case of AERD) nonselective COX inhibitors. Nasal polyps contain high levels of PGD 2 , and numbers of hPGDS 1 cells in nasal polyps correlate with asthma risk. 57, 58 Also, both PGD 2 levels and numbers of cells expressing CRTH2 1 cells were higher in bronchoalveolar lavage (BAL) fluid from patients with severe asthma than those with milder disease. 57, 59 Similar findings were reported in the tissues from patients with EoE. 60, 61 Several CRTH2 antagonists (ARRY 502, BI-671800, QAW-039, and OC000459) have been tested in clinical trials and have shown encouraging results in patients with asthma 62 and those with EoE, 63 further supporting the role of PGD 2 in type 2 immunopathology and its potential as a therapeutic target (Fig 2) .
Effects on type 2 lymphocytes. CRTH2 expression is highly specific to T H 2 cells among CD4 1 cells in human subjects and is also restricted to ILC2s among human innate lymphocyte subsets. PGD 2 elicits chemotaxis and generation of IL-5 and IL-13 by both T H 2 cells and ILC2s and sustains survival of T H 2 cells. Notably, T H 2/T H 2A cells express both hPGDS and COX-2 in addition to CRTH2 and generate PGD 2 when activated ex vivo, which is suggestive of an autocrine amplification loop. 9 These studies suggest that endogenous PGD 2 -CRTH2 signaling can regulate the survival and cytokine production of both innate and adaptive effector lymphocytes found in type 2 immunopathology. Additionally, DP 1 signaling has been shown to block IFN-g and IL-2 expression in unfractionated human T cells. 64 Thus PGD 2 could potentiate type 2 immunity by suppressing T H 1 cytokine production, as well as direct CRTH2-mediated promotion of T H 2 cytokine generation. Because CRTH2 is also expressed by eosinophils and basophils, 65 direct chemotaxis of effector cells is another likely consequence of CRTH2 signaling.
PGE 2
Receptors. Of all PGs, PGE 2 is the most ubiquitous because of its production by multiple cell types and functional complexity caused by signaling through 4 separate GPCRs, termed E-prostanoid receptor (EP) 1 to 4. 66 These receptors are expressed broadly and in various combinations by both immune and nonimmune cells. Consequently, PGE 2 has well-defined proinflammatory and anti-inflammatory effects that depend on context. 67,68 PGE 2 production in vivo increases sharply during inflammatory responses, 67 reflecting the sequential function of COX-2 and mPGES-1. Although PGE 2 can facilitate T H 17-type immunopathology through EP 2 -and EP 4 -mediated effects on DCs and T cells in animal models 69, 70 and can facilitate the function of group 3 innate lymphoid cells through EP 4 receptor, 71 it is substantially bronchoprotective and anti-inflammatory in the setting of type 2 airway immunopathology in human subjects and has similar effects in both mouse and rat models (Table I) .
Clinical correlation. When administered through inhalation to subjects with atopic asthma, PGE 2 attenuates both early-and late-phase responses to allergen and decreases the recruitment of both eosinophils and basophils to the lung during the late phase. 72 In addition, PGE 2 inhalation significantly decreases levels of PGD 2 and cysLTs in BAL fluid of atopic asthmatic patients collected after allergen challenge. 73 These findings are consistent with the reported effects of PGE 2 in suppressing mast cell activation and inhibiting 5-LO activation through protein kinase A-dependent serine phosphorylation. [74] [75] [76] Based on studies using precision-cut human lung slices, PGE 2 stabilizes airway mast cells and prevents 5-LO activation primarily through EP 2 receptor signaling and also acts as a modest direct bronchodilator by acting at EP 4 receptors on airway smooth muscle. 77 The role of PGE 2 in regulating airway pathology is most evident in patients with AERD, in which both impaired production of PGE 2 and reduced EP 2 receptor expression, function, or both are reported. [78] [79] [80] [81] Depletion of residual PGE 2 by aspirin and other drugs that inhibit COX-1 might account for the cysLTand mast cell-dependent physiologic responses observed in patients with this disease. 46 Accordingly, inhalation of PGE 2 by patients with AERD before provocative challenge with aspirin prevents both the characteristic reduction in FEV 1 and the increase in urinary LTE 4 levels, which are indicative of 5-LO activation. These deficiencies might explain the high levels of eosinophilic inflammation, ongoing mast cell activation, and overproduction of cysLTs characteristic of the disease. This hypothetical role for PGE 2 in patients with AERD is strongly supported by animal models (Fig 2) . 82 Effects on lymphocytes. PGE 2 exerts complex effects on T-cell functions that depend on context. PGE 2 -EP 2 signaling in naive human T cells facilitates polarization to T H 17-type effector function, inducing the receptors for both IL-23 and IL-1. 69 Additionally, PGE 2 signaling through EP 4 receptors suppresses production of both IL-10 and IFN-g. In murine T cells PGE 2 can facilitate both T H 17 and T H 1 effector function in vitro and is important for the development of T H 17-driven neuropathology in patients with experimental autoimmune encephalomyelitis. In contrast, PGE 2 potently suppresses IL-5 generation by polyclonally activated human T cells and also suppresses IL-2, IL-4, and IL-5 generation by a human T-cell line while suppressing proliferation of these cells. The receptor or receptors responsible were not determined in this study, although cyclic AMP was implicated. The effects of PGE 2 on T-cell responses might be concentration specific, with suppressive effects observed at micromolar range concentrations and stimulatory effects at nanomolar concentrations. 83 To date, no studies have addressed whether PGE 2 differentially affects the function of T H 1, T H 2, or T H 17 effector cells and whether these effects are reflected in the bronchoprotective effects of PGE 2 in vivo. Recent studies suggest that PGE 2 /EP 4 receptor signaling stimulates mouse group 3 innate lymphoid cells (which exhibit T H 17-like effector functions) to generate IL-22 and restrain systemic responses to bacteria. 71 EP 2 receptor transcript is expressed strongly by human ILC2 cells, 84 and PGE 2 signals through both EP 2 and EP 4 receptors to suppress proliferation and T H 2 cytokine generation by this cell type. 85 Modulation of cytokine expression by macrophages. Although PGE 2 suppresses type 2 inflammation in most settings, a recent study demonstrated that mice lacking mPGES-1 showed significantly reduced lung eosinophilia and ILC2 expansion compared with WT control mice in response to repetitive inhalation challenges with an extract from the allergenic mold A alternata. These reductions corresponded to diminished expression of IL-33 by lung cells in the mPGES-1-deleted mice. Bone marrowderived macrophages from mice lacking mPGES-1 or EP 2 receptors displayed sharply diminished LPS-induced expression of IL-33 transcript and protein relative to WT control cells. This study highlights the complexity of the effects of PGE 2 in the lung and suggests that PGE 2 is anti-inflammatory in most settings in human and mouse studies but has proinflammatory effects toward IL-33 production in murine macrophages. 49 
PROSTACYCLIN Receptors
PGI 2 , also known as prostacyclin, is a short-lived COX product generated by endothelial cells and follicular DCs. It signals through the stimulatory G protein-linked I prostanoid (IP) receptor. Although best known as a vasodilator and potent inhibitor of platelet activation, PGI 2 also has prominent inhibitory functions in models of allergic pulmonary inflammation. [86] [87] [88] Mice bearing targeted deletions of IP receptors and prostaglandin I synthase (PGIS), respectively, show sharply augmented inflammatory responses to antigen sensitization and challenge, 89, 90 whereas stable PGI 2 analogs show suppressive effects. As noted below, these effects reflect the actions of PGI 2 at several cellular control points (Table I) .
Clinical correlation
PGI 2 is the most abundant COX product generated spontaneously by human lung fragments ex vivo, 91 as reflected by detection of the stable metabolite 6-keto PGF1-a. These quantities increase substantially when lung fragments are sensitized passively with IgE and challenged with anti-IgE. 92 PGI 2 generation also increases substantially in BAL fluid collected from atopic human subjects after segmental allergen inhalation challenge. Because mast cells do not generate PGI 2 , it seems likely that these increases reflect the activation of endothelial cells. Inhalation of PGI 2 by subjects with mild asthma caused decreases in FEV 1 , presumably reflecting vascular engorgement, but also blocked bronchoconstriction to subsequent administrations of methacholine or PGD 2 . 93 Although it is presently unknown whether the suppressive effects of PGI 2 on type 2 inflammation are recapitulated in human subjects, IP receptor agonists (epoprostenol, treprostinil, and iloprost) are US Food and Drug Administration approved for the treatment of pulmonary arterial hypertension 94 and should permit such studies (Fig 2) .
Suppression of lymphocyte activation
IP receptors are highly expressed on both CD4
1 effector T cells and T H 2 cells. Adoptive transfer of transgenic ovalbumin (OVA)-specific mouse T H 2 cells that had been pretreated with PGI 2 showed a significant attenuation of pulmonary inflammation and AHR compared with transfer of PGI 2 -untreated T H 2 cells. This effect was attributed to a loss of CCL17-induced CD4 95 PGI 2 -IP signaling also regulates IL-6 release from lung eosinophils and DCs to modulate intraepithelial gd-17 T cells. Mice lacking IP receptors demonstrate reduced gd-17 cells in the thymi of naive mice and also in the lungs in response to allergen challenge. Conversely, iloprost augmented IL-17 production by gd T cells in an IL-6-dependent manner and significantly reduced airway inflammation, suggesting a key immunoregulatory role of PGI 2 in the development of innate intraepithelial gd-17 cells. 96 PGI 2 can directly downregulate production of T H 2 cytokines from T H 2-polarized mouse splenic CD4
1 cells on restimulation in the presence of PGI 2 analogs, with partial dependence on IP receptor. 97 Furthermore, PGI 2 has also been shown to increase production of T H 2-suppressive IL-10 from T H 2-polarized CD4 1 cells. 98 Another in vivo study reported that PGI 2 reduces airway T H 2-mediated inflammation by suppressing CD4
1 T H 2 cell recruitment to the lungs and demonstrated that mice sensitized and challenged with OVA and receiving T H 2-polarized CD4 1 OVA-specific cells from D011.10 mice, along with IL-2 and PGI 2 , exhibit lower levels of T H 2 response. 99 More recent studies reveal a potential role for IP signaling in the function of ILC2s. Stimulation of mouse lung ILC2s with cicaprost inhibited their proliferation induced by IL-33 100 while facilitating their entry into apoptosis. In addition, cicaprost significantly inhibited IL-5 and IL-13 production from murine bone marrow-derived ILC2s stimulated with IL-33. Similar observations were also made with sorted human ILC2s in culture. 100 Moreover, in a murine model of repeated Alternaria species challenge, IP receptor-null mice showed significantly increased numbers of IL-5-and IL-13-producing ILC2s compared with WT controls. 100 This study suggests that endogenous PGI 2 can restrain the extent of ILC2 activation and resultant immunopathology during innate responses to proteases. 4 . Once synthesized, LXs exert anti-inflammatory effects at a number of cellular targets, at least some of which are mediated by ALX/FPR (lipoxin A4 receptor or formyl peptide receptor), a GPCR (Fig 2 and Table I ).
LIPOXINS Biosynthesis and receptors
Clinical correlation
LXs are classified as proresolving mediators, and anomalies in their signaling or production have been associated with asthma severity. Blood levels of LXA 4 and leukocyte LXA 4 generation are reduced in subjects with severe asthma relative to those with milder disease. 101 Stable LXA 4 analogs have shown promise in various models of inflammatory diseases, including asthma, although no human studies exist to date (Fig 2) .
Effects on ILC2s
Human ILC2s and natural killer cells express ALX/FPR. A recent study demonstrated that LXA 4 suppressed PGD 2 -induced production of IL-13 by ILCs and also enhanced the proapoptotic effects of natural killer cells on autologous eosinophils. These studies extend the potential relevant cellular targets of LXA 4 to the lymphoid compartment and suggest a mechanism or mechanisms by which reduced production of LXA 4 can potentiate the severity of type 2 inflammation in asthmatic patients. 102 
CONCLUSIONS
The recognition that eicosanoids regulate the function of lymphoid effectors of allergic disease has sparked renewed interest in lipid mediator biology. It is possible that at least some of the modest efficacy of existing drugs targeting 5-LO and CysLT 1 R in retrospect reflect the role of cysLTs in control of ILC2s and the lymphoid compartment. Prominent synergistic effects of LTE 4 (mediated by CysLT 1 R) and PGD 2 (mediated by CRTH2) on both T H 2 cells and ILC2s, along with suppressive effects of PGI 2 , PGE 2 , and LXA 4 identified in animal models of type 2 immunopathology, suggest additional opportunities for therapeutic targeting. Because all of these effects are mediated by GPCRs, which are readily targetable with antagonists, agonists, or both, it is possible that single drugs or combinations of such drugs could provide sufficient efficacy to serve as alternatives to therapies with potential toxicity (glucocorticoids) or prohibitive expense (biologics).
